Norvasc Information
What's inside Norvasc
Norvasc Active Ingredients: amlodipine besylate, details.| Norvasc Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Norvasc 2.5 mg | tablet | oral | 1.0 each | OTC |
| Norvasc 5 mg | tablet | oral | 1.0 each | OTC |
| Norvasc 10 mg | tablet | oral | 1.0 each | OTC |
Recent Norvasc Side Effects
Posted by turkeylouise 25 days ago
I HAVE BEEN TAKING NORVASC FOR YEARS.I TOLD MY DOCTOR IT WAS HURTING ME AND SHE SAID I JUST DIDN'T LIKE MY MEDICINE.WELL LET...
Posted by pamsirhindi about 1 month ago
Day 29 of Norvasc generic 10MG. I have swollen ankles and at the end of the day they a little painful. I cannot stay up past...
Posted by aquasparkle about 1 month ago
These side effects are scary! I just got off of the drug LISINOPRIL! PLEASE, PLEASE look it up if your doctor is changing y...
Norvasc in the News
Pfizer Reaffirms FY08 Outlook; To File 15-20 Regulatory ... - RTT News
The rise in revenues was in spite of the March 2007 loss of US exclusivity of Norvasc, which contributed to a decrease in Norvasc revenues of $667 million. ...
Wed Mar 05 12:30:43 -0500 2008
Pfizer Fourth Quarter Earnings Call - 123Jump.com
Revenues increased 1% to $48.6 billion compared with 2006 despite the loss of US exclusivity in both Norvasc and Zoloft. - Net income of $8.3 billion or ...
Mon Mar 03 10:26:16 -0500 2008
Why MNCs don’t bring blockbuster drugs into India - Hindu Business Line
... Pfizer’s cholesterol drug Lipitor and anti-hypertension drug Norvasc are some original drugs that did not get launched in the Indian market, he said. ...
Wed Feb 27 13:16:55 -0500 2008
Norvasc Chemical Information
amlodipine besylate - The besylate salt of amlodipine, a synthetic, dihydropyridine, calcium channel blocker with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries,decreases myocardial contractility, increases blood flow and oxygen delivery to the myocardial tissue and decreases total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.
Norvasc RSS Feed